Trial · NCT01453049
Results by group150
Each measurement the trial posted, group by group, in the words and numbers it posted.
41 to 60 of 150
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Chloride, Calcium, and Phosphorus at Week 24/EW | Rosiglitazone+Glimepiride FDC | BUN; n=39, 42 | 0.076 | Standard Deviation 0.8661 | mmol/L |
| Change From Baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Chloride, Calcium, and Phosphorus at Week 24/EW | Glimepiride | BUN; n=39, 42 | 0.146 | Standard Deviation 1.3378 | mmol/L |
| Change From Baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Chloride, Calcium, and Phosphorus at Week 24/EW | Rosiglitazone+Glimepiride FDC | Sodium; n=39, 41 | -0.56 | Standard Deviation 2.926 | mmol/L |
| Change From Baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Chloride, Calcium, and Phosphorus at Week 24/EW | Glimepiride | Sodium; n=39, 41 | 0.33 | Standard Deviation 2.749 | mmol/L |
| Change From Baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Chloride, Calcium, and Phosphorus at Week 24/EW | Rosiglitazone+Glimepiride FDC | Potassium; n=39, 41 | 0.006 | Standard Deviation 0.4169 | mmol/L |
| Change From Baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Chloride, Calcium, and Phosphorus at Week 24/EW | Glimepiride | Potassium; n=39, 41 | 0.086 | Standard Deviation 0.473 | mmol/L |
| Change From Baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Chloride, Calcium, and Phosphorus at Week 24/EW | Rosiglitazone+Glimepiride FDC | Chloride; n=39, 41 | -1.93 | Standard Deviation 17.653 | mmol/L |
| Change From Baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Chloride, Calcium, and Phosphorus at Week 24/EW | Glimepiride | Chloride; n=39, 41 | 1.24 | Standard Deviation 3.295 | mmol/L |
| Change From Baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Chloride, Calcium, and Phosphorus at Week 24/EW | Rosiglitazone+Glimepiride FDC | Calcium; n=38, 35 | 0.035 | Standard Deviation 0.1481 | mmol/L |
| Change From Baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Chloride, Calcium, and Phosphorus at Week 24/EW | Glimepiride | Calcium; n=38, 35 | 0.037 | Standard Deviation 0.1122 | mmol/L |
| Change From Baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Chloride, Calcium, and Phosphorus at Week 24/EW | Rosiglitazone+Glimepiride FDC | Phosphorus; n=36, 35 | 0.046 | Standard Deviation 0.1315 | mmol/L |
| Change From Baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Chloride, Calcium, and Phosphorus at Week 24/EW | Glimepiride | Phosphorus; n=36, 35 | 0.028 | Standard Deviation 0.1980 | mmol/L |
| Change From Baseline in the Ratio of TC/HDL-C and LDL-C/HDL-C at Week 24/EW | Rosiglitazone+Glimepiride FDC | TC/HDL-C; n=35, 33 | 0.2295 | Standard Deviation 1.1037 | ratio |
| Change From Baseline in the Ratio of TC/HDL-C and LDL-C/HDL-C at Week 24/EW | Glimepiride | TC/HDL-C; n=35, 33 | -0.1283 | Standard Deviation 0.9562 | ratio |
| Change From Baseline in the Ratio of TC/HDL-C and LDL-C/HDL-C at Week 24/EW | Rosiglitazone+Glimepiride FDC | LDL-C/HDL-C; n=34, 31 | 0.0753 | Standard Deviation 0.8888 | ratio |
| Change From Baseline in the Ratio of TC/HDL-C and LDL-C/HDL-C at Week 24/EW | Glimepiride | LDL-C/HDL-C; n=34, 31 | -0.0782 | Standard Deviation 0.6222 | ratio |
| Change From Baseline in High Sensitivity C-reactive Protein (Hs-CRP) at Week 24/EW | Rosiglitazone+Glimepiride FDC | -10.71 | Standard Deviation 41.368 | mmol/L | |
| Change From Baseline in High Sensitivity C-reactive Protein (Hs-CRP) at Week 24/EW | Glimepiride | 2.74 | Standard Deviation 29.892 | mmol/L | |
| Percent Change From Baseline in High Sensitivity C-reactive Protein (Hs-CRP) at Week 24/EW | Rosiglitazone+Glimepiride FDC | -39.58 | Full Range -94.8 to 2677.1 | percent change | |
| Percent Change From Baseline in High Sensitivity C-reactive Protein (Hs-CRP) at Week 24/EW | Glimepiride | 0.00 | Full Range -80.0 to 1320.2 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01453049/results?page=3